Literature DB >> 32100197

Predictors of malignancy in high-risk indeterminate (TIR3B) cytopathology thyroid nodules.

A Cozzolino1, C Pozza1, R Pofi1, E Sbardella1, A Faggiano1, A M Isidori2, E Giannetta1, A Pernazza3, E Rullo3, V Ascoli3, A Lenzi1, D Gianfrilli1.   

Abstract

PURPOSE: The classification of indeterminate cytopathology at thyroid fine-needle-aspiration (FNA) has been updated to reduce the number of unnecessary surgery; the 2014 Italian classification introduced the low-risk (TIR3A) and high-risk (TIR3B) subcategories. Aim of this study was to identify the ultrasonographic (US), clinical and cytological predictors of malignancy among TIR3B nodules from a single institution.
METHODS: A prospective observational study including 1844 patients who underwent thyroid FNA from June 2014 to January 2019. Ultrasonographic, clinical and cytological features were recorded. All TIR3B diagnoses were referred to surgery. According to final histology, patients were divided into thyroid cancer (TC) or benign nodules. Chi-square test, or Fisher exact test when appropriate, were used to compare groups and logistic regression analyses were used to determine independent predictors of malignancy.
RESULTS: Of 1844 FNAs, 96 (5.2%) were TIR3B. Histology report was available in 65. Among them, 25 (38.5%) were TC. Predictors of TC were nodule size < 20 mm [Odds Ratio (OR) = 5.88, 95% CI 1.91-18.11, p = 0.002], absence or weak intralesional flow [OR = 0.3, 95% CI 0.09-0.77, p = 0.015], microcalcifications [OR = 6.5, 95% CI 1.90-21.93, p = 0.003] at US; nuclear inclusions [OR = 25.3, 95% CI 1.34-476.07, p = 0.031] and chromatin clearing [OR = 3.7, 95% CI 1.27-10.99, p = 0.017] at cytopathology. Patients aged < 55 years had a significantly higher risk of TC [OR = 9.7, 95% CI 2.79-34.07, p < 0.001]. In multivariate analysis, age < 55 and nodule size < 20 mm resulted as independent risk factors.
CONCLUSIONS: Patients < 55 years receiving a diagnosis TIR3B on nodules < 20 mm, with microcalcifications, showing specific nuclear atypia at cytopathology are more likely to have TC. Combining US, cytological and clinical features could help determining which patients with a TIR3B diagnosis should be referred to surgery.

Entities:  

Keywords:  Fine needle aspiration; Indeterminate cytopathology; TIR3B; Thyroid cancer; Thyroid nodules; Ultrasonography

Mesh:

Year:  2020        PMID: 32100197     DOI: 10.1007/s40618-020-01200-0

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  4 in total

1.  Diagnostic accuracy of ultrasonographic features in detecting thyroid cancer in the transition age: a meta-analysis.

Authors:  Alessia Cozzolino; Tiziana Filardi; Ilaria Simonelli; Giorgio Grani; Camilla Virili; Ilaria Stramazzo; Maria Giulia Santaguida; Pietro Locantore; Massimo Maurici; Daniele Gianfrilli; Andrea M Isidori; Cosimo Durante; Carlotta Pozza
Journal:  Eur Thyroid J       Date:  2022-06-14

2.  Outcome and diagnostic reproducibility of the thyroid cytology "indeterminate categories" SIAPEC/SIE 2014 in a consecutive series of 302 cases.

Authors:  F Massa; P Caraci; A Sapino; G De Rosa; M Volante; M Papotti
Journal:  J Endocrinol Invest       Date:  2020-08-14       Impact factor: 4.256

3.  TIRADS, SRE and SWE in INDETERMINATE thyroid nodule characterization: Which has better diagnostic performance?

Authors:  Ilaria Celletti; Daniele Fresilli; Corrado De Vito; Marco Bononi; Sara Cardaccio; Alessia Cozzolino; Cosimo Durante; Giorgio Grani; Gianmarco Grimaldi; Andrea M Isidori; Carlo Catalano; Vito Cantisani
Journal:  Radiol Med       Date:  2021-06-15       Impact factor: 3.469

4.  Predictive factors of malignancy in pediatric patients with thyroid nodules and performance of the Italian classification (SIAPEC 2014) in the outcome of the cytological FNA categories.

Authors:  Gerdi Tuli; Jessica Munarin; Erica Agosto; Patrizia Matarazzo; Francesco Quaglino; Alberto Mormile; Luisa de Sanctis
Journal:  Endocrine       Date:  2021-06-14       Impact factor: 3.633

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.